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ardiac Sympathetic Imaging
ithmIBG in Heart Failure
gnasi Carrio´, MD,* Martin R. Cowie, MD, MSC,† Junichi Yamazaki, MD,§
ames Udelson, MD, Paolo G. Camici, MD*‡
arcelona, Spain; London, United Kingdom; Tokyo, Japan;
nd Boston, Massachusetts
ardiac sympathetic imaging withmeta-iodobenzylguanidine (mIBG) is a noninvasive tool to risk stratify
atients with heart failure (HF). In patients with ischemic and nonischemic cardiomyopathy, cardiacmIBG
ctivity is a very powerful predictor of survival. Cardiac sympathetic imaging can help in understanding
ow sympathetic overactivity exerts its deleterious actions, which may result in better therapy and
utcome for patients with HF. (J Am Coll Cardiol Img 2010;3:92–100) © 2010 by the American College of
ardiology Foundationd
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oolurrent Challenges in Heart Failure (HF)
he prognosis of HF has improved in the past
0 years, but it remains a serious condition with
markedly increased risk of death in the early
eriod after onset of the syndrome (1). In
opulation studies, there is a 10% mortality by
0 days. For those who survive this early
igh-risk period, the 5-year mortality is 54% in
en and 40% in women (1). Mortality for
atients in most recent clinical trials, with a
ackground of appropriate pharmacological
eurohormonal blockade, is around 8% to 10%
er annum. Device therapy, with cardiac resyn-
hronization with or without an implantable
ardioverter-defibrillator further improves the
rognosis (2–4), but at a relatively high addi-
ional financial cost initially.
In clinical trials of chronic HF therapy, 50%
f deaths are due to sudden death, and pro-
ressive HF accounts for around 30% of
rom *Hospital Sant Pau, Barcelona, Spain; †National Heart &
mperial College, London, United Kingdom; §Toho University Sch
chool of Medicine, Boston, Massachusetts.anuscript received December 9, 2008; revised manuscript received Aeaths, this latter proportion increasing as
ymptomatic severity increases (5). In popula-
ion studies including patients with new-onset
F, progressive HF appears to be the single
ost common cause of death (52%), with
udden death accounting for only 22% of
eaths within the first 6 months of diagnosis
6,7).
Identifying those patients most at risk of
eath, and those most likely to benefit from
urrently available treatment technologies, re-
ains a challenge. Identifying the risk of sud-
en, presumed arrhythmic, death, is particu-
arly difficult. In general, older age, greater
unctional impairment, poorer systolic function
f the left ventricle, lower serum sodium,
oorer renal function, broader QRS complex,
ower blood pressure, and inability to tolerate
isease-modifying drugs such as angiotensin-
onverting enzyme (ACE) inhibitors are asso-
iated with a poorer prognosis and are men-
ng Institute and the ‡Clinical Sciences Centre,
of Medicine, Tokyo, Japan; and Tufts Universitypril 15, 2009, accepted July 16, 2009.
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93ioned in guidelines for HF management (8,9).
oorer adherence to evidence-based treatment by
he physician has also been shown to be indepen-
ently associated with a worse prognosis (10).
here is a pressing need for improved risk stratifi-
ation for patients developing HF, with the goal of
etter identification of those for whom more ag-
ressive therapy is likely to be beneficial.
athophysiologic Basis for Cardiac
ympathetic Imaging
ompared with myocardium of healthy controls,
he myocardium of patients with chronic left ven-
ricular dysfunction is characterized by a significant
eduction of pre-synaptic norepinephrine (NE) up-
ake and post-synaptic beta-adrenoceptor density
11,12). There is increased sympathetic activity in
he hearts of patients with congestive HF, which is
generalized rather than a regional phenomenon
nd might contribute to the remodeling process
f the whole left ventricle. This concept is con-
istent with the finding that down-regulation of
yocardial beta-adrenoceptor density, measured
sing positron emission tomography (PET) with
1C-CGP-12177, soon after acute myocardial
nfarction is predictive of the occurrence of left
entricular dilatation at follow-up (13). Myocar-
ial beta-adrenoceptor density appears reduced in
atients with HF due to dilated cardiomyopathy
14) and down-regulation of myocardial beta-
drenoceptor is more pronounced in patients with
ypertrophic cardiomyopathy who proceed to left
entricular dilation and HF (15). Therefore, myo-
ardial beta-adrenoceptor down-regulation may be
general nonspecific response to stress and could be
ue to a locally increased amount of NE in the
ynaptic cleft. The sustained hyperactivity of the
ympathetic nervous system observed in HF is the
onsequence of several mechanisms including in-
reased central sympathetic outflow, altered neuronal
E reuptake, and facilitation of cardiovascular re-
ponse to sympathetic stimulation by angiotensin II.
As a single-photon emission computed tomog-
aphy (SPECT) tracer whose use does not require
vailability of an on-site cyclotron, 123I-meta-
odobenzylguanidine (mIBG) has been the most
idely used imaging agent for studying causes and
ffects of cardiac sympathetic hyperactivity. mIBG
as developed through a modification of the potent
euron-blocking agent guanethidine that acts selec-
ively on sympathetic nerve endings. Uptake of
23I-mIBG into neurons is achieved mainly through lhe uptake-1 mechanism, a homeostatic system
esponsible for the reuptake of NE. Unlike NE,
IBG is not metabolized, allowing it to be imaged.
he uptake-1 mechanism is one of the main NE
isposal systems, and its malfunction may lead to
bnormal catecholamine concentration in the syn-
ptic cleft.
maging Techniques and QuantificationWithmIBG
complete imaging protocol typically includes
lanar and SPECT images obtained 15 to 30 min
early) and 3 to 4 h (delayed) after intravenous
njection of 111 to 370 MBq (3 to 10 mCi)
23I-mIBG (Fig. 1) (16). Myocardial uptake and
istribution is visually assessed. mIBG up-
ake is semiquantified by calculating a
eart-to-mediastinum ratio (HMR) after
rawing regions of interest over the heart
nd mediastinum (Fig. 1). This approach
rovides a highly reproducible index of
ardiac sympathetic activity (16). By com-
aring early and delayed activities, the
IBG wash-out (WO) rate from the
yocardium can be derived, providing a
arameter that reflects retention of NE by
ympathetic neurons (17).
SPECT images of the heart allow eval-
ation of the regional sympathetic activity.
olar maps of the myocardium can be
onstructed from the SPECT images and
llow assessment of the defect extent and
everity. Such polar maps can be easily
ompared with those of healthy individu-
ls (Fig. 2). 123I-mIBG SPECT images
an also be compared with SPECT myo-
ardial perfusion images to examine dif-
erences between regional innervation and
erfusion. In making such comparisons, it is impor-
ant to be aware of differences between normal
nnervation and perfusion patterns, such as lower
ptake of 123I-mIBG seen in the posterior inferior
all, especially in elderly persons (18,19).
magingWith 123I-mIBG in Ischemic Heart Disease
he sympathetic nervous tissue is more sensitive to
he effects of ischemia than the myocardial tissue (20).
t has been shown that the uptake of 123I-mIBG is
ignificantly reduced in areas of myocardial infarction
21), and adjacent noninfarcted regions (22) as well as
n areas with acute and chronic ischemia (23,24). It is
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94probably earlier and more severely than cardiac myo-
ytes), which may take a long time to regenerate and
hat episodes of ischemia result in decreased 123I-
IBG uptake. Sympathetic nerve trunks course along
he same path as the coronary arteries, with the
otential of a neuronal defect being present distal to
he site of myocardial injury. Immunohistochemistry
as demonstrated good correspondence between 123I-
IBG imaging and the presence or absence of sym-
athetic cardiac nerves (25). Reinnervation may be
ncomplete as late as 3 months after acute myocardial
nfarction, but by 12 months after a first infarction, an
ncrease in activity in the peri-infarcted region without
change in perfusion has been observed (26).
Concordance between the extent of 123I-mIBG
efect at rest and perfusion defect at exercise has been
hown in patients with coronary artery disease. This
oncordance suggests that resting imaging with 123I-
IBG combined with resting myocardial perfusion
maging (MPI) may be useful as a marker of reversible
schemia in patients unable to exercise and with
ontraindications to pharmacological stress (27). An-
ther potential role of mIBG imaging at rest is the
etection of transient ischemia, which has been shown
Figure 1. Quantiﬁcation of Cardiac mIBG Activity
(A) Calculation of meta-iodobenzylguanidine (mIBG) heart-to-med
thorax. Regions of interest (ROI) are drawn over the heart and med
(C) Severely decreased cardiac mIBG activity in a patient with HMR:ith metabolic tracers of both fatty acid and glucose onalogs, termed “ischemic memory,” that may result in
egional decrease in mIBG uptake (28–32). This
roperty of resting 123I-mIBG imaging also has prom-
se in the evaluation of the area at risk in the subacute
hase of acute coronary syndromes by revealing more
xtensive defects than MPI.
magingWith 123I-mIBG for
isk Stratification and Prognosis
mpaired cardiac adrenergic innervation as assessed by
23I-mIBG imaging is strongly related to mortality in
atients with HF independently of its cause. The
rognostic value of 123I-mIBG scintigraphy compared
ith other noninvasive cardiac imaging indices was
nitially studied in patients with either ischemic or
diopathic cardiomyopathy (33,34). Among all clinical
nd imaging variables, only the late HMR and left
entricular ejection fraction (LVEF) were indepen-
ent predictors of mortality, with late HMR being the
est predictor of event-free survival. In these studies, a
ate HMR of 1.2 was used to identify reduced
23I-mIBG uptake. Using this same threshold, it has
een shown that reduced late HMR is correlated with
num ratio (HMR) and wash-out rate on an anterior view of the
num. (B) Normal cardiac mIBG activity in a patient with HMR: 1.80.
.iasti
iastither predictors of prognosis such as LVEF, cardiac
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95ndex, pulmonary wedge pressure, and peak oxygen
onsumption, with late HMR 1.2 and peak oxygen
ptake also predictive of death or cardiac transplanta-
ion over follow-up (35).
In other large cohorts of patients (36,37) with HF
tudied with 123I-mIBG, a reduced late HMR has
een the most powerful predictor of cardiac mortality.
late HMR 1.74, age 60 years, a history of
yocardial infarction, and New York Heart Associa-
ion (NYHA) functional class III or IV strongly
ndicated poor clinical outcomes (36). However, 123I-
IBG imaging was the most powerful independent
ong-term prognostic indicator for ischemic or idio-
athic cardiomyopathy patients. Late HMR was the
ost powerful independent predictor of cardiac mor-
ality in both groups of patients, superior to the early
MR and the WO rate, with an identical threshold
or both groups for identifying patients at risk of
ardiac death when LVEF was 50% (37).
The incremental prognostic implications of cardiac
23I-mIBG imaging have been assessed as well.
lasma brain natriuretic peptide (BNP) level signifi-
antly, but roughly, correlated with cardiac sympa-
hetic nerve imaging results in a series of patients with
F (38). Univariate analysis identified BNP level,
MR, chronic renal dysfunction, diabetes mellitus,
ge, and use of nitrates as significant predictors of fatal
ump failure. Using a plasma BNP threshold of 172
g/ml and a late HMR threshold of 1.74 together, the
Figure 2. Polar Map Display of the Regional mIBG Distribution
The extent map displays in black the pixels with counts 2 standar
displays the defect severity, after dividing the total count difference
ber of pixels. The wash-out rate can be estimated for each segm
Lat  lateral; mIBG  meta-iodobenzylguanidine; Sep  septal; SPEazard ratio was 34.4. Prevalence of fatal pump failure oignificantly increased from 22% to 62.5% when
iabetes mellitus and chronic renal dysfunction were
resent with a higher BNP level and low cardiac
23I-mIBG activity.
The largest body of prognostic results is based on
he late HMR from planar 123I-mIBG imaging
Fig. 3). Further confirmation of the strong prognostic
alue of this parameter was presented in the results of a
ecent retrospective multicenter European study
39), which included blind review and prospective
uantitative reanalysis of the late HMR of 290
atients with ischemic and nonischemic HF
NYHA functional class II to IV, 262 patients with
VEF 50%) with follow-up data for 2 years. A
tandardized method for drawing heart and medi-
stinum region of interests on planar chest images
as evaluated by 3 independent blinded readers.
he analysis technique was robust, with 95% to
8% agreement among the readers regarding the
MR results obtained. The mean HMR was sig-
ificantly different between patients with and with-
ut events (1.51 vs. 1.97). Based on receiver oper-
ting characteristic curve analysis, a threshold value
or HMR of 1.75 yielded a sensitivity of 84% with
specificity of 60% to predict events (2-year event-
ree survival 62% for late HMR 1.75 vs. 95% for
ate HMR 1.75). Logistic regression showed late
MR and LVEF as the only significant predictors
a SPECT Study
eviations or less compared with the normal ﬁle. The severity map
tween the black pixels and the normal region by the total num-
as well as for the whole ventricle. Ant  anterior; Inf  inferior;
 single-photon emission computed tomography.From
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96Besides the late HMR, the prognostic value of
ther 123I-mIBG parameters has also been reported.
he WO rate was evaluated in patients with LVEF
40% during a follow-up of 52 months (40). A WO
ate 27% was a strong predictor of survival. In
nother series of outpatients with HF (mean LVEF
9%), of whom 48 had abnormal WO rate (27%),
udden cardiac death was significantly more frequent
n patients with an abnormal WO rate (41). 123I-
IBG WO rate and both early and late HMR were
ignificantly associated with sudden cardiac death.
he prognostic value of cardiac 123I-mIBG imaging
ogether with that of time and frequency domain
arameters of HRV in patients with mild-to-
oderate chronic HF has been prospectively evalu-
ted (42). On univariate analysis, WO rate, late
MR, and normalized very–low-frequency power
Figure 3. Examples of Low- and High-Risk Patients
(A) mIBG images of a typical low-risk patient, with HMR: 1.70. Notic
normal regional distribution on the tomographic images. (B) mIBG
poor cardiac activity on the planar and tomographic images. Abbre
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Figure 4. Retrospective European Study
(A) HMR and 2-year major cardiac events (MCE). (B) Receiver-operat
(H/M) ratio 1.75 yielded a sensitivity of 84% and a speciﬁcity of 60%
(39). NYHA  New York Heart Association.howed a significant association with the cardiac
vents at follow-up. Multivariate analysis showed that
O rate was the only independent predictor of
ardiac events.
A recent meta-analysis (43) performed on 18
tudies with a total of 1,755 patients provided
urther confirmation that patients with HF and
ecreased cardiac 123I-mIBG uptake or increased
O rate have a worse prognosis as compared with
atients with normal 123I-mIBG parameters.
magingWith 123I-mIBG
or Assessment of Treatment
ardiac 123I-mIBG imaging can demonstrate drug-
nduced changes in cardiac adrenergic activity. Ena-
april improved cardiac sympathetic activity but did
e normal cardiac mIBG activity on the late planar view and the
es of a typical high-risk patient, with HMR: 1.10. Notice the very
ions as in Figure 1.
Estimated Area
C = 0.77089
0.2 0.4 0.6 0.8 1
1-Sensitivity
haracteristic analysis: a threshold value of heart to mediastinum
predict events. Reprinted, with permission, from Agostini et al.e th
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97ot affect plasma NE levels in a group of patients
ith HF (44), supporting the concept that restora-
ion of cardiac neuronal uptake of NE is one of the
eneficial effects of ACE treatment. Similar in-
reases in cardiac 123I-mIBG uptake have been
bserved after treatment with other ACE and
ngiotensin receptor blocker (ARB) (45,46) in pa-
ients with chronic HF.
With regard to beta-blocker therapy, patients
ith improvement of LVEF of5% after 3 months
f treatment with metoprolol demonstrate a de-
rease in regional WO rate of 123I-mIBG after 1
onth of beta-blocker therapy compared with
aseline rates (45). The effect of chronic carvedilol
reatment in patients with HF and cardiac sympa-
hetic nerve dysfunction of varying severity due to
diopathic cardiomyopathy has been studied (47–
9). Most patients showed a favorable response in
eft ventricular function to the treatment, regardless
f the baseline level of cardiac sympathetic nervous
ystem function, as assessed by cardiac 123I-mIBG
maging. Patients with severely depressed HMR
1.40) had a higher likelihood to achieve an
mprovement in cardiac sympathetic nervous system
unction in response to carvedilol treatment. In
atients treated with bisoprolol a late HMR 1.7
ad a sensitivity of 91% and specificity of 92% for
redicting response to beta-blocker therapy (48).
The influence of aldosterone treatment on cardiac
ympathetic nerve activity has been assessed compar-
ng 2 groups of patients treated with an ACE inhib-
tor and a loop diuretic, 1 with the addition of
pironolactone. After 6 months of treatment with
pironolactone, the late HMR of 123I-mIBG and
VEF significantly increased, and the late total defect
core as well as the WO rate of 123I-mIBG signifi-
antly decreased, with parallel reduction of the left
entricular end-diastolic volume (50). A prospective
tudy comparing amiodarone versus beta-blockers in
he treatment of patients with idiopathic cardiomyop-
thy (51) reported similar improvement in cardiac
ymptoms, function, and sympathetic nerve activity
ith both drugs.
123I-mIBG studies for prognostication in 208
atients under combination therapy and with sta-
ilized mild-to-moderate HF and LVEF 45%, of
oth ischemic and nonischemic origin have been
nalyzed (52). 123I-mIBG and echocardiographic
tudies were performed at baseline and after 6
onths of treatment, which included ACE inhib-
tors, ARB, beta-blockers, loop diuretics, and spi-
onolactone. The variation in the WO rate between
he sequential 123I-mIBG studies was significantly power in the noncardiac death group than that in
he cardiac death group and was the only indepen-
ent predictor of cardiac death.
ewer Multicenter Clinical Trials
lmost all cardiac 123I-mIBG studies reported in
he past 20 years represented single-center experi-
nces. However, during the past 5 years, a series of
ulticenter trials were performed to demonstrate
he robustness of quantification of 123I-mIBG car-
iac uptake as a prognostic marker in HF patients.
rognosis in HF: MBG311 and MBG312. MBG311 and
BG312 are 2 prospective trials initiated in 2005 to
alidate the prognostic capability of quantification
f sympathetic innervation of the myocardium us-
ng 123I-mIBG. These trials have now been desig-
ated as part of the ADMIRE-HF (AdreView
yocardial Imaging for Risk Evaluation in Heart
ailure) program. The hypothesis tested was that
atients with HF and abnormal HMR ratios have
arlier and more frequent events (HF progression,
otentially life-threatening arrhythmia, or cardiac
eath) than those with HMR within the normal
ange. Event status was monitored for 24 months,
ith final determinations made by an independent
linical adjudication committee of cardiologists.
econdary efficacy analyses employed a multipa-
ameter Cox proportional hazards model fitted to
ultiple imaging and clinical variables, including
arly and late HMR, total and segmental 123I-
IBG SPECT defect scores, total and segmental
ardiac 99mTc-tetrofosmin SPECT MPI defect
cores, LVEF, NYHA functional class, BNP, and
E levels, 123I-mIBG/99mTc-tetrofosmin SPECT
ismatch score, and echocardiography left ventricular
nd-diastolic volume and left ventricular mass. All
rimary and secondary analyses were performed on
he composite end point (first occurrence of any
pecified adverse cardiac event) and on each individual
vent category (Table 1). Results of the trials were
ecently presented at the American College of Cardi-
logy scientific sessions, in March 2009, and the
ublication of the manuscript is expected to follow
oon.
rediction of inducibility of ventricular tachycardia:
BG203. MBG203 was a prospective pilot study to
etermine whether alterations in cardiac sympa-
hetic innervation as measured by 123I-mIBG were
elated to inducibility of ventricular tachyarrhyth-
ias during electrophysiology (EP) testing in pa-
ients with previous myocardial infarction. The
rimary objective was to evaluate results on planar
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9823I-mIBG imaging and the combination of SPECT
23I-mIBG innervation and 99mTc-tetrofosmin MPI
n comparison with results on EP testing (positive or
egative for inducible sustained ventricular tachycardia
s determined by a clinical adjudication committee of
EP specialists). Primary inclusion criteria were
istory of myocardial infarction, left ventricular dys-
unction, and referral for a clinically indicated cardiac
P study because of syncope or nonsustained ven-
ricular tachycardia (Table 2).
In a multivariable analysis, the only variable that
howed a significant difference between EP-positive
nd EP-negative patients was the 4-h 123I-mIBG
PECT defect score. A 4-h 123I-mIBG SPECT
efect score of 37 yielded a sensitivity of 77% and
pecificity of 75% for predicting EP results (53). The
esults of this pilot study suggest that the simple index
f 123I-mIBG cardiac uptake represented by the
MR ratio will not be sufficiently sensitive to cate-
orize levels of arrhythmic risk in ischemic heart
isease patients. However, the extent of denervated
yocardium, as assessed by 123I-mIBG SPECT im-
ging, does appear to correlate with inducibility of
entricular tachyarrhythmias during EP testing.
Table 1. Demographics of Patients in ADMIRE-HF (MBG311/312
Trial Mean Age (yrs) % Male Mean LVEF (%) %
MBG311 63.1 82 27.1
MBG312 61.5 78 26.0
Total 62.4 80 26.6
*Estimated.
ADMIRE-HF  AdreView Myocardial Imaging for Risk Evaluation in Heart Fai
fraction; NYHA  New York Heart Association.
Imaging Findings of Patients in MBG203 Trial
le
EP Patients
(n  30)
EP Patients
(n  20) p Value
65.0 9.0 65.2 9.9 0.50
32.1 7.6 32.7 7.3 0.50
(I/II/III)* 3/14/7 2/10/3 0.50
(nmol/l)† 1.30 1.24 1.90 2.14 0.25
60.2 62.4 82.4 78.3 0.31
MR ratio 1.44 0.21 1.47 0.13 0.50
47.1 15.6 43.5 12.3 0.39
ummed score 42.7 8.8 34.9 9.8 0.005
T summed score 17.6 9.0 12.7 10.4 0.086
etrofosmin 21.4 13.1 17.3 11.1 0.26
nless otherwise indicated. *Thirty-nine subjects with history of HF; †based upon
cts with adequate blood samples.
cible sustained ventricular tachycardia by electrophysiology testing; EP 
ained ventricular tachycardia by electrophysiology testing; HF  heart failure;
guanidine; SPECT  single-photon emission computed tomography; otherp.ardiac 123I-mIBG imaging in 2009. Despite the exten-
ive research on cardiac 123I-mIBG imaging per-
ormed over the past 20 years, the exact role of this
rocedure in diagnosis and management of patients
ith heart disease remains uncertain. Although the
mportance of the sympathetic innervation of the
eart is unquestioned, and the benefits of therapies
hat ameliorate the effects of neurohormonal imbal-
nce are well established, doubt lingers about the
anner in which quantitative assessment of adrener-
ic neuronal status should be used. Particularly for HF
edical therapies, the conventional reasoning is that
ll appropriate medications will be used as tolerated
nd as dictated by symptom improvement, so a mon-
toring tool such as 123I-mIBG imaging offers no
dditional benefit. From a medical and economic
oint of view, it is easier to treat all patients with
oderately priced drugs that have been shown to
enefit the large majority than to attempt to individ-
alize treatment based upon a physiological assess-
ent that might produce equivocal results in a subset
f the patients. 123I-mIBG imaging can provide an
stimate of prognosis and can demonstrate whether
herapies are producing the desired effect on cardiac
re- and post-synaptic function, but other readily
vailable methods already inform the clinician regard-
ng the success of his/her treatment approach. It is
hus unlikely that 123I-mIBG imaging will become a
outine clinical procedure for monitoring heart disease
tatus or treatment response. It is in the realm of
evice therapy that 123I-mIBG imaging is likely to
ave its greatest impact in the next few years.
Most of the patients who have a Class I indication for
eceiving an implantable cardioverter-defibrillator will
ever experience an appropriate discharge, and
bout one-third of patients who receive cardiac
esynchronization therapy do not improve. For both
hese patient groups, 123I-mIBG imaging holds
romise as a technique capable of identifying both
igh and low risk for the adverse outcomes the
evices are intended to prevent or at least forestall.
he results from the ADMIRE-HF study should
ls)
YHA Functional Class II % Ischemic
% With ICDs at Any
Time During Trial*
82 67 25
83 65 49
82 66 36
ICD  implantable cardioverter-deﬁbrillator; LVEF  left ventricular ejectionTria
N
lure;Table 2. Clinical and
Variab
Age (yrs)
LVEF (%)
NYHA functional class
Plasma norepinephrine
Plasma BNP (pmol/l)†
Late planar 123I-mIBG H
Washout (%)
Late 123I-mIBG SPECT s
99mTc-tetrofosmin SPEC
Late 123I-mIBG/99mTc-t
mismatch score
Values are mean 1 SD, u
28 EP and 17 EP subje
EP  positive for indu
negative for inducible sust
mIBG  meta-iodobenzylrovide additional impetus for the development of
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99riteria for use of 123I-mIBG imaging (alone or
ore likely in combination with other procedures)
o identify those HF patients at highest and lowest
isk for potentially fatal arrhythmic events.
onclusions
23I-mIBG imaging provides a noninvasive tool for
he investigation of cardiac sympathetic innervation.
lthough defining the exact criteria to be used for
linical decision-making will depend on the results of
urrently ongoing trials, it appears that 123I-mIBG
maging will soon be added to the resources availablediol 2005;46:e1– 82. 36:555–9.he cardiac sympathetic system will aid in quantifying
he functional severity of myocardial injury and re-
odeling associated with ischemic and nonischemic
ardiomyopathy, judging the likely response to med-
cal and device therapy for HF, and identifying the
ubstrate that places the patient at the highest risk for
rrhythmic sudden cardiac death.
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